or Try an Advanced Search...

    CD19 Stocks List

    Symbol Grade Name % Change
    AFMD C Affimed Therapeutics B.V. -1.57
    CRBU D Caribou Biosciences, Inc. -15.95
    CLLS F Cellectis S.A. 3.40
    ESLA F Estrella Immunopharma, Inc. 4.66
    NKTX F Nkarta, Inc. -10.03
    View As Page of Charts
    Related Industries: Biotechnology Shell Companies
    Related Stock Lists: Biopharmaceutical Cancer Medicine Solid Tumors Hematologic Malignancies Blastoma Chimeric Antigen Receptor Chimeric Antigen Receptor T Cell Chronic Lymphocytic Leukemia Glioblastoma Immune System Leukemia Lymphocytic Leukemia Lymphoma Multiple Myeloma Natural Killer Cell Tumors Of The Hematopoietic And Lymphoid Tissues Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Adoptive Cell Transfer

    Related ETFs - A few ETFs which own one or more of the above listed CD19 stocks.

    Symbol Grade Name Weight
    CNCR C Loncar Cancer Immunotherapy ETF 1.48
    NXTE C AXS Green Alpha ETF 1.26
    WDNA F WisdomTree BioRevolution Fund 0.68
    GNOM F Global X Genomics & Biotechnology ETF 0.36
    IWC B iShares Microcap ETF 0.09
    View all CD19 ETFs...
    Compare ETFs
    Compare CNCR to IWC Compare GNOM to IWC Compare WDNA to IWC

        CD19 Stocks Recent News

        Date Stock Title
        Nov 12 NKTX Nkarta to Participate in an Upcoming Investor Conference
        Nov 10 CRBU Caribou Biosciences, Inc. (NASDAQ:CRBU) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
        Nov 8 NKTX Nkarta ending development of asset for lymphoma
        Nov 8 CRBU Caribou Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
        Nov 7 NKTX Nkarta GAAP EPS of -$0.39 misses by $0.03
        Nov 7 NKTX Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
        Nov 7 CRBU Caribou Bioscience GAAP EPS of -$0.38 beats by $0.06, revenue of $2.02M misses by $1.07M
        Nov 6 CRBU Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
        Nov 6 CRBU Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update
        Nov 6 AFMD Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
        Related Industries: Biotechnology Shell Companies
        Related Stock Lists: Biopharmaceutical Cancer Medicine Solid Tumors Hematologic Malignancies Blastoma Chimeric Antigen Receptor Chimeric Antigen Receptor T Cell Chronic Lymphocytic Leukemia Glioblastoma Immune System Leukemia Lymphocytic Leukemia Lymphoma Multiple Myeloma Natural Killer Cell Tumors Of The Hematopoietic And Lymphoid Tissues Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Adoptive Cell Transfer
        CD19

        Browse All Tags